Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
A Liberal Democratic Party (LDP) lawmakers’ league promoting the prescription of topical patches on December 15 submitted a proposal to Finance Minister Satsuki Katayama, calling for the continued insurance coverage of local transdermal analgesics and measures to shore up their…
To read the full story
Related Article
- LDP Patch League to Seek Drug Price Support in Honebuto Proposal
June 2, 2026
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- LDP Group Urges Ministers to Keep Coverage of Pain Relief Patches
June 2, 2025
- LDP Group Calls for Keeping Health Coverage for Pain Relief Patches
April 25, 2025
REGULATORY
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
- iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
- MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
- MHLW Panel Weighs Single IRB, DCT Metrics in Core Hospital Overhaul
June 12, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…